A Comparative Study on the “Dual Channel” Management Policy of National Medical Insurance Negotiation Drugs——Taking Guangdong Province as an Example

China Health Insurance ›› 2025, Vol. 0 ›› Issue (9) : 106-113.

China Health Insurance ›› 2025, Vol. 0 ›› Issue (9) : 106-113. DOI: 10.19546/j.issn.1674-3830.2025.9.013
Medical Economy

A Comparative Study on the “Dual Channel” Management Policy of National Medical Insurance Negotiation Drugs——Taking Guangdong Province as an Example

Author information +
History +

Abstract

Objective: By analyzing the policy texts of the "dual-channel" management of negotiated medical insurance drugs in Guangdong Province, this study aims to summarize key components and areas for refinement in policy, and to propose optimization suggestions for the "dual-channel" management policy. Methods: Relevant policy documents on "dual-channel" management issued by the people's governments and healthcare security administrations of 21 prefecture-level cities in Guangdong Province were collected. ROST CM6 software was used for word frequency and semantic network analysis, and the policy contents of each city were compared and analyzed to summarize the policy differences among different regions. Results: The word frequency analysis identified 26 high-frequency key words (with a frequency of ≥ 200 times), among which 4 key words appeared more than 1000 times. The semantic network diagram indicated that the core of the "dual-channel" policy was "medical insurance" and "drugs". Further comparative analysis of the policy contents of different regions revealed that there were differences in drug management, selection and management of designated retail pharmacies, prescription transfer and drug purchase management, and payment management. Conclusion: The number of "dual-channel" pharmacies varies significantly among different regions. The regulatory requirements and standards for "dual-channel" pharmacies after selection are not yet complete, and there are obvious differences in medical insurance payment policies among different regions. It is suggested that each prefecture-level city should reasonably set the access standards for "dual-channel" pharmacies, establish and improve the regulatory requirements and measures for "dual-channel" pharmacies, improve the separate payment policy for medical insurance, and give full play to the supplementary role of other insurances.

Key words

"dual-channel" management / "dual-channel" drugs / national negotiated drugs / policy text analysis

Cite this article

Download Citations
A Comparative Study on the “Dual Channel” Management Policy of National Medical Insurance Negotiation Drugs——Taking Guangdong Province as an Example[J]. China Health Insurance. 2025, 0(9): 106-113 https://doi.org/10.19546/j.issn.1674-3830.2025.9.013

References

[1] 张博,丁锦希,陈烨,等.国家医保谈判药品“双通道”政策动因与实施模式[J].世界临床药物,2021,42(9):709-716.
[2] 国家医保局,国家卫生健康委.关于建立完善国家医保谈判药品“双通道”管理机制的指导意见[EB/OL].(2021-04-22)[2025-08-01].http://www.nhsa.gov.cn/art/2021/5/10/art_104_6527.html.
[3] 王飞,何勤,唐萍,等.贵州省某公立医院特殊药品使用管理“双通道”机制实践[J].中国医院,2022,26(12):78-80.
[4] 陈莹莹,饶予林,黄嘉绿,等.医保“双通道”处方管理系统的应用探讨[J].中国卫生信息管理杂志,2024,21(05):710-715.
[5] 莫曼君,吴志强,黄宁,等.“双通道”管理机制下电子处方流转与医保线上结算分析[J].中国医院管理,2024,44(06):73-76+86.
[6] 朱文静,褚福浩.药品“双通道”机制下定点零售药店执业药师作用探讨[J].中国药业,2023,32(20):17-20.
[7] 蒋蓉,王怡诺,祝晶京,等.美国专业药房质量管理体系及对我国双通道药店管理的启示[J].中国卫生事业管理,2022,39(03):185-189+220.
[8] 张钰婉,谈在祥,卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究,2022,39(04):15-18+23.
[9] 徐鑫,王守涛,杨郁葱.医保谈判药“双通道”政策管理模式及优化建议[J].中国医院,2023,27(09):75-77.
[10] 彭博,姜骁桐,张小娟,等.国家医保谈判药品“双通道”管理实施现状与政策分析[J].中国卫生政策研究,2024,17(05):9-16.
[11] 杨赐然,王瑞,罗银,等.国谈药“双通道”管理政策设计的省际比较研究[J].中国卫生政策研究,2023,16(04):25-31.
[12] 茂名市医疗保障局,茂名市卫生健康局,茂名市市场监督管理局.关于贯彻落实国家医保谈判药品“双通道”管理机制的通知[EB/OL].(2021-12-01)[2025-08-01].http://www.maoming.gov.cn/mmylbzj/gkmlpt/content/0/966/mpost_966624.html#17741.
[13] 清远市医疗保障局,清远市卫生健康局,清远市市场监督管理局.清远市国家医保谈判药品“双通道”和门诊特定病种处方流转管理的实施细则[EB/OL].(2021-12-30)[2025-08-01].http://www.gdqy.gov.cn/qyylbzj/gkmlpt/content/1/1492/mpost_1492951.html#8036.
[14] 中山市医疗保障局,中山市卫生健康局,中山市市场监督管理局.关于建立完善国家医保谈判药品“双通道”管理机制的工作通知[EB/OL].(2021-11-18)[2025-08-01].https://hsa.zs.gov.cn/zwgk/zcgw/qtwj/content/post_2029166.html.
[15] 湛江市医疗保障局.湛江市医疗保障局关于贯彻落实省医保局等部门建立完善国家医保谈判药品“双通道”管理机制的实施意见的通知[EB/OL].(2021-12-14)[2025-08-01].https://www.zhanjiang.gov.cn/zjsylbzj/gkmlpt/content/1/1547/post_1547643.html#9366.
[16] 东莞市医疗保障局.东莞市建立完善国家医保谈判药品“双通道”管理机制实施细则[EB/OL].(2021-11-09)[2025-08-01].https://www.dg.gov.cn/ylbzj/gkmlpt/content/3/3653/post_3653925.html#3322.
[17] 惠州市医疗保障局. 惠州市医疗保障局关于公开遴选国家医保谈判药品“双通道”和职工基本医疗保险门诊特定病种定点零售药店的公告[EB/OL].(2021-12-21)[2025-08-01].https://www.huizhou.gov.cn/zfxxgkml/hzsylbzj/bmwj/gg/content/post_4498135.html.
[18] 河源市医疗保障局,河源市卫生健康局,河源市市场监督管理局.关于建立完善国家医保谈判药品“双通道”管理机制的实施方案(试行)[EB/OL].(2021-12-21)[2025-08-01].http://www.heyuan.gov.cn/zwgk/zcfg/bsgfxwj/content/post_471576.html.
[19] WANG Q, DAI R, YU Q, et al.Research on government regulation methods for the spatial layout of retail pharmacies: practice in Shanghai, China[J]. International journal for equity in health,2024,23(1):173-185.
[20] 刘畅,文光慧.天津某三甲医院国谈药品外配处方现状调查分析[J].中国卫生标准管理,2019,10(10):46-48.
[21] 李欣雨,徐娟.我国医保谈判药品“双通道”管理政策执行困境及推进策略[J].中国药房,2024,35(08):906-911.
[22] 孙雅群,宋燕.山东省国家医保谈判药品“双通道”管理政策比较研究[J].卫生软科学,2023,37(10):13-16.

Accesses

Citation

Detail

Sections
Recommended

/